Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165761 · ClinicalTrials.gov registry record · NA
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
A NA study, sponsored by W.L.Gore & Associates.
- Terminated
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT02165761 is a NA study that was terminated before completion, run by W.L.Gore & Associates. The registered enrollment target is 42 participants.
The verdict
NCT02165761, a NA study, was terminated before completion, sponsored by W.L.Gore & Associates.
- TERMINATED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).
Interventions
- DEVICE GORE® Hybrid Vascular Graft
- DEVICE Non-heparin bonded synthetic graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-01-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02165761
The ClinicalTrials.gov registry entry for NCT02165761 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W.L.Gore & Associates, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GORE® Hybrid Vascular Graft is the first listed.
NCT02165761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02165761 about?
NCT02165761 is a clinical study titled "Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients". To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).
What is the current status of trial NCT02165761?
This trial is currently terminated. It is a NA study. The enrollment target is 42 participants. The study started on 2014-07. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT02165761?
The interventions under investigation include: GORE® Hybrid Vascular Graft (DEVICE), Non-heparin bonded synthetic graft (DEVICE).
Who is sponsoring clinical trial NCT02165761?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.